sunitinib
Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor used as an active pharmaceutical ingredient in anti-cancer medications. It was the first cancer drug simultaneously approved for two different indications.
Portée du contenu: Les informations de cette page concernent l'identification chimique ainsi que les contextes d'approvisionnement industriel, de recherche et de production. Elles ne constituent ni une allégation thérapeutique, ni un avis médical, ni une notice d'utilisation médicamenteuse.
Approvisionnement ou fourniture de ce composé?
Publiez votre inventaire ou une demande d'achat
CAS 557795-19-4
Sunitinib malate
active pharmaceutical ingredient
Dichlorhydrate de bétahistine
active pharmaceutical ingredient
(1S,5R)-1,2,3,4,5,6-Hexahydro-1,5-methano-8H-pyrido(1,2-a)(1,5)diazocin-8-one
active pharmaceutical ingredient
Piretanide
loop diuretic active pharmaceutical ingredient
Methoxyphenamine hydrochloride
beta-adrenergic receptor agonist
(E)-Sunitinib
active pharmaceutical ingredient
Sunitinib acid
Pharmaceutical intermediate for sunitinib synthesis
3-[4-methyl-2-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid
research reagent for kinase inhibition
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WINHZLLDWRZWRT-ATVHPVEESA-N
CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C